About the Study

B-ALL: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults

This study is being done children and adults. • Between 1-30 years old for one of the groups • Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) There are two groups in this study. For the treatment group, patients age 1 through 30 are eligible. In this group, researchers would like to know if not giving a child total body irradiation (also called TBI) therapy before a child's transplant is as good as giving a child radiation before transplant and a child's growth and development will not be affected by radiation. For the observation group, all patients are eligible. The purpose of this part of the study is to use the NGS-MRD test to see if the patient would qualify for the Non-TBI Group, and to gather more research data.

Interested in learning more?

Full Study Name: EndRAD - A Phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative